Ollin Biosciences

Private

#Ophthalmology #Retinal Disease #Wet AMD #Diabetic Macular Edema

Ollin Biosciences is a clinical-stage ophthalmology company developing a next-generation anti-VEGF challenger to Regeneron's Eylea and Roche's Vabysmo for retinal disease. The company raised a $330M Series B in 2026 to fund pivotal Phase 3 trials of its lead asset.

Company Info

Sector:Biotechnology / Ophthalmology / Anti-VEGF

Headquarters:South San Francisco, California, USA

Founded:2020

Website:ollin.bio/

Clinical Development Pipeline

OLN-102

Target: Bispecific anti-VEGF

Wet age-related macular degeneration (Vabysmo challenger)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Ollin nets $330M to run Phase 3 trials of Vabysmo challenger from China ↗

Ollin Biosciences announced a $330 million Series B to fund pivotal studies around what it hopes can be a more potent competitor to Genentech’s eye drug Vabysmo.

Leadership Team

Jason Ehrlich, M.D., Ph.D.

Co-Founder and Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →